Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, 8900 Beverly Boulevard, Suite 250, Los Angeles, CA 90048, USA.
Gastroenterology Section, VA Long Beach Healthcare System, 5901 East Seventh Street - 11G, Long Beach, CA 90822, USA.
Clin Liver Dis. 2019 Feb;23(1):157-165. doi: 10.1016/j.cld.2018.09.008.
Hepatic steatosis and steatohepatitis have several etiologies; the most common are alcoholic steatohepatitis (ASH) and obesity/metabolic syndrome-induced steatohepatitis, also known as nonalcoholic steatohepatitis (NASH). Although the etiology of these 2 conditions is different, they share pathways to disease progression and severity. They also have differences in physiologic pathways, and shared and divergent mechanisms can be therapeutic targets. There is no approved pharmacologic therapy for NASH, but several molecules are under study. Focus remains on modulation of insulin resistance, oxidative stress, the inflammatory cascade, hepatic fibrosis, and cell death. This review provides an overview of pathophysiologic similarities and differences between ASH and NASH.
肝脂肪变性和脂肪性肝炎有几种病因；最常见的是酒精性脂肪性肝炎（ASH）和肥胖/代谢综合征引起的脂肪性肝炎，也称为非酒精性脂肪性肝炎（NASH）。尽管这两种疾病的病因不同，但它们具有疾病进展和严重程度的共同途径。它们在生理途径上也存在差异，共同和不同的机制可以成为治疗靶点。目前还没有针对 NASH 的批准的药物治疗方法，但有几种分子正在研究中。重点仍然是调节胰岛素抵抗、氧化应激、炎症级联反应、肝纤维化和细胞死亡。这篇综述提供了 ASH 和 NASH 之间病理生理相似性和差异的概述。
